Wegovy Approved to Cut Heart Disease and Stroke Risk
FDA approves Novo Nordisk drugs for heart health in overweight individuals.
- Bilawal Riaz
- 1 min read
Novo Nordisk has received FDA approval for their drugs Wegovy and Ozempic to help reduce the risk of heart attack, heart disease, and stroke in overweight or obese individuals with cardiovascular disease. Wegovy is now the first weight loss medication approved to prevent these life-threatening events. Semaglutide, the active ingredient in these drugs, has shown significant heart health benefits. Despite its increasing popularity, insurance coverage for semaglutide remains limited, prompting concerns about access to this potentially life-saving medication.
- Tags:
- Novo Nordisk
- FDA
- Ozempic